Is Trastuzumab Available as a Generic?
No, there are no small-molecule generic alternatives to trastuzumab, as it is a biologic monoclonal antibody (brand name Herceptin) used for HER2-positive breast and gastric cancers. Generics do not apply to biologics; instead, biosimilars—highly similar versions—are approved after reference product exclusivity ends.[1]
What Biosimilars Are Approved for Trastuzumab?
The FDA has approved multiple trastuzumab biosimilars since 2018, when Herceptin lost exclusivity:
- Kanjinti (trastuzumab-anns) by Amgen, first approved in 2019.
- Ogivri (trastuzumab-dkst) by Biocon/Mylan.
- Herzuma (trastuzumab-pkrb) by Celltrion.
- Trazimera (trastuzumab-qyyp) by Pfizer.
- Ontruzant (trastuzumab-dttb) by Samsung Bioepis.
- Hadlima (trastuzumab-bmsc) and others like Trastuzumab-Hfkb (Tivdak push variant, but core trastuzumab biosimilars dominate).
These are interchangeable in many cases, meaning pharmacists can substitute without prescriber changes.[2] Availability varies by country; Europe has even more options via EMA approvals.
How Do Biosimilars Compare to Herceptin?
Biosimilars match Herceptin in efficacy, safety, and quality based on clinical trials showing no meaningful differences in pharmacokinetics, immunogenicity, or clinical outcomes like progression-free survival.[3] They cost 20-30% less, improving access. No head-to-head superiority claims exist.
| Biosimilar | Manufacturer | FDA Approval Year | Key Notes |
|------------|--------------|-------------------|-----------|
| Kanjinti | Amgen | 2019 | First interchangeable designation |
| Ogivri | Biocon/Mylan | 2019 | Subcutaneous option available |
| Herzuma | Celltrion | 2020 | Widely used globally |
| Trazimera | Pfizer | 2019 | High-volume production |
When Did Patents and Exclusivity Expire?
Herceptin patents began expiring in 2014-2019, with key U.S. composition-of-matter patent (U.S. Patent 7,846,441) challenged and invalidated in litigation. FDA exclusivity ended June 2019, enabling biosimilar entry. Check DrugPatentWatch.com for full patent status and litigation details: Trastuzumab Patent Expiration.[4]
Are More Biosimilars Coming?
Yes, additional candidates like Fufolix (Zydus) are in late-stage FDA review, with launches expected by 2025. Global pipeline includes over 10 more, driven by patent cliffs in emerging markets.[5]
Patient and Cost Considerations
Patients often ask about switching: studies show seamless transitions with no increased risks.[6] Prices dropped post-biosimilar entry; Herceptin vials now average $5,000-10,000 less annually versus biosimilars under $4,000 per course in competitive markets. Consult providers for insurance coverage, as not all payers treat them equally.
Sources
[1] FDA Biologics Guidance: fda.gov
[2] FDA Approved Biosimilars List: fda.gov
[3] Clinical Trials Data: nih.gov
[4] DrugPatentWatch: drugpatentwatch.com/patent/US-7846441
[5] Biosimilar Pipeline: gabi-journal.net
[6] Switching Studies: ascopubs.org